Taking it in the chin: vitamin K1 for the prevention of acneiform rash.

about

Taking it in the chin: vitamin K1 for the prevention of acneiform rash.

Item

http://www.wikidata.org/entity/Q52642629

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Taking it in the chin: vitamin K1 for the prevention of acneiform rash.

@en

Taking it in the chin: vitamin K1 for the prevention of acneiform rash.

@nl

type

Item

label

Taking it in the chin: vitamin K1 for the prevention of acneiform rash.

@en

Taking it in the chin: vitamin K1 for the prevention of acneiform rash.

@nl

prefLabel

Taking it in the chin: vitamin K1 for the prevention of acneiform rash.

@en

Taking it in the chin: vitamin K1 for the prevention of acneiform rash.

@nl

P1476

Taking it in the chin: vitamin K1 for the prevention of acneiform rash.

@en

P2093

M E Lacouture

http://www.w3.org/2001/XMLSchema#string

P2860

Activation of ErbB2 by 2-methyl-1,4-naphthoquinone (menadione) in human keratinocytes: role of EGFR and protein tyrosine phosphatases

Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-Emptive Skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer

Mechanisms of cutaneous toxicities to EGFR inhibitors.

Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining?

Dermatologic infections in cancer patients treated with epidermal growth factor receptor inhibitor therapy.

Randomized double-blind trial of prophylactic oral minocycline and topical tazarotene for cetuximab-associated acne-like eruption.

A prospective, randomized, double-blinded, split-face/chest study of prophylactic topical dapsone 5% gel versus moisturizer for the prevention of cetuximab-induced acneiform rash.

A phase II study (ARCHER 1042) to evaluate prophylactic treatment of dacomitinib-induced dermatologic and gastrointestinal adverse events in advanced non-small-cell lung cancer.

EVITA - A double-blind, vehicle controlled, randomized phase II trial of vitamin K1 cream as prophylaxis for cetuximab-induced skin toxicity.

Effects of epidermal growth factor receptor inhibitor-induced dermatologic toxicities on quality of life.

P304

796-798

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

editorial

P356

10.1093/ANNONC/MDY084

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-03-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29566217

http://www.w3.org/2001/XMLSchema#string

P921

vitamin K

P932

5913626

http://www.w3.org/2001/XMLSchema#string